© 2025 CellCarta - All rights reserved.

Explore our validation report   

NSCLC Patient Management: fast testing of tissue and liquid biopsies 

Genomics Expertise

Advancing NSCLC Patient Management  

Biomarker testing is crucial to ensure patients receive the best treatment. Mutational profiling is essential in determining patient eligibility, stratification, and allows a deeper understanding of outcomes. Recognizing challenges in conventional methods of NCSLC patient management, we sought to validate the accurate, rapid and highly sensitive Aspyre ® assay for detecting actionable NSCLC variants in both tissue and liquid biopsies.  

Details you'll get in the validation report  

- Key performance characteristics: LoB, accuracy, intra-run and inter-run precision 

- Intra-lab concordance at our global sites 

- Validation data for both FFPE and blood samples

- Detects 114 somatic variants across 11 clinical practice recommended genes (EGFR, BRAF, KRAS, ERBB2, ALK, ROS1, RET, MET, NTRK1-3) 

See how we elevated the validation of the Aspyre® assay to patient management standards and validated it for use with blood samples, enabling genomic profiling for patient enrollment when tissue samples are not available. 

CellCarta delivers comprehensive genomic solutions across all stages of development from discovery and preclinical through late-stage programs, from sample DNA/RNA extraction to data analysis. Our team of experts perform qPCR, dPCR, NGS, single-cell sequencing and spatial transcriptomics, accelerating your drug development with reliable data.